drugset / Trial / NCT00162227
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
Summary
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.
Timeline
- Start
- 2000-09
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 200 mg | Oral |
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |